NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]

Final Stakeholder List

Company	Opening the second of the seco	
Company Alexion Pharmaceuticals (danicopan) Patient/carer groups Aplastic Anaemia Trust Beacon Genetic Alliance UK PNH Support South Asian Health Federation Specialised Healthcare Alliance Healthcare professional groups Anaemia Nurse Specialist Association British Blood Transfusion Society British Geriatrics Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Immunology British Society for Immunology National PNH Service NHS Blood and Transplant Royal College of Pathologists Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal College of Physicians Royal College of Physicians Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health and Social Care General Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Hospital Information Services - Jehovah's Witnesses Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Councils in Usual Pharmaceutical Scotes NHS Confederation Scottish Medicines Consortium NHS	Consultees	,
 Alexion Pharmaceuticals (danicopan) Patient/carer groups Aplastic Anaemia Trust Beacon Genetic Alliance UK PNH Support South Asian Health Federation Specialised Healthcare Alliance Healthcare professional groups Anaemia Nurse Specialist Association British Blood Transfusion Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Haematology Ritish Society for Haematology National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Physicians Royal College of Physicians Royal College of Physicians Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK Clinical Pharmacy Association WK Services Comparator companies Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (lptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England 		appeal)
 Alexion Pharmaceuticals (danicopan) Patient/carer groups Aplastic Anaemia Trust Beacon Genetic Alliance UK PNH Support South Asian Health Federation Specialised Healthcare Alliance Healthcare professional groups Anaemia Nurse Specialist Association British Blood Transfusion Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Haematology National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Physicians Royal College of Physicians Royal College of Physicians Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Healthcare Improvements Cotland Hospital Informatio	Company	General
Patient/carer groups Aplastic Anaemia Trust Beacon Genetic Alliance UK PNH Support South Asian Health Federation Specialised Healthcare Alliance Healthcare professional groups Anaemia Nurse Specialist Association British Blood Transfusion Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Genetic Medicine British Society for Immunology British Society for Immunology National PNH Service NHS Blood and Transplant Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal Society of Medicine UK Clinical Pharmaceutical Society UK National Screening Committee Others Department of Health nat Social Care Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Hospital Information Services - Jehovah's Witnesses Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Association of Primary Care National Association of Primary Care National Pharmacy Association Welsh Health Specialised Services Committee Comparator companies Alexion Pharmaceuticals (leculizumab, ravulizumab) Novartis Pharmaceuticals (lptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England	Alexion Pharmaceuticals (danicopan)	Allied Health Professionals Federation
 Aplastic Anaemia Trust Beacon Genetic Alliance UK PNH Support South Asian Health Federation Specialised Healthcare Alliance Healthcare professional groups Anaemia Nurse Specialist Association British Blood Transfusion Society British Geriatrics Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Haematology British Society for Haematology National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Physicians Royal College of Physicians Royal College of Physicians Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotial Healthcare Improvement Scotland Healthcare Improv		•
 Beacon Genetic Alliance UK PNH Support South Asian Health Federation Specialised Healthcare Alliance Healthcare professional groups Anaemia Nurse Specialist Association British Blood Transfusion Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Haematology British Society for Haematology British Society for Haematology British Society for Immunology NAtional PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Posthologists Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health Alliance Department of Health Federation Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Healthcare Improvement Scotla		
 Genetic Alliance UK PNH Support South Asian Health Federation Specialised Healthcare Alliance Healthcare professional groups Anaemia Nurse Specialist Association British Blood Transfusion Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Haematology British Society for Haematology British Society for Haematology British Society for Haematology Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal College of Physicians Royal College of Physicians Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Healthcare Improvement Scotland Hospital Information Services - Jehovah's Witnesses Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association Welsh Health Specialised Services Comparator companies Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (lptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England 	·	_
 PNH Support South Asian Health Federation Specialised Healthcare Alliance Healthcare professional groups Anaemia Nurse Specialist Association British Blood Transfusion Society British Geriatrics Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Haematology British Society for Haematology British Society for Immunology National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Pathologists Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee PNH Support National Services Division National Services Division NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Commarator companies Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (lptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England 		
 South Asian Health Federation Specialised Healthcare Alliance Healthcare professional groups Anaemia Nurse Specialist Association British Blood Transfusion Society British Geriatrics Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Haematology British Society for Immunology National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal Society of Medicine UK Clinical Pharmacy Association UK Clinical Pharmacy Association UK National Screening Committee Others Department of Health and Social Care Healthcare Improvement Scotland Hospital Information Services - Jehovah's Witnesses Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Services Division National Pharmacy Association Welsh Health Specialised Services Committee Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (lptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England MDO Olivical Trials Mait 		
 Specialised Healthcare Alliance Healthcare professional groups Anaemia Nurse Specialist Association British Blood Transfusion Society British Geriatrics Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Haematology British Society for Immunology National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health and Social Care Hospital Information Services - Jehovah's Witnesses Medicines and Healthcare products Regulatory Agency National Pharmacy Association National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Comparator companies Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (lptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England MPS Olivies Teich Lieft 	· ·	
Healthcare professional groups Anaemia Nurse Specialist Association British Blood Transfusion Society British Geriatrics Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Haematology British Society for Immunology British Society for Immunology National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Physicians Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health and Social Care Jehovah's Witnesses Medicines and Healthcare products Regulatory Agency National Association of Primary Care		·
 Healthcare professional groups Anaemia Nurse Specialist Association British Blood Transfusion Society British Geriatrics Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Haematology British Society for Immunology National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health and Social Care Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (lptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England 	Specialised Healthcare Alliance	
 Anaemia Nurse Specialist Association British Blood Transfusion Society British Geriatrics Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Haematology British Society for Immunology National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Comparator companies Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (lptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Regulatory Agency National Association NHS Alliance NHS Confederation Committee Welsh Health Specialised Services Alexion Pharmaceuticals (lptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Regulatory Agency National Pharmacy Association Welsh Health Specialised Services Alexion Pharmaceuticals (lptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Elevant research groups Cochrane Haematological Malignancies Genomics England British Society National Association NHS College of Nursing National Association NHS College of Nursing Novartis Pharmaceuticals (Committee) Cochrane Haematological Malignancies Genomics Engla	Healthcare professional groups	
 British Blood Transfusion Society British Geriatrics Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Haematology British Society for Haematology British Society for Immunology National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee National Association of Primary Care National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Comparator companies Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (Iptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England 		•
 British Geriatrics Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Haematology British Society for Haematology British Society for Immunology National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Services Division NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (Iptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England MDO Olivical Trick Haif 		
 British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Haematology British Society for Immunology National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Services Division NHS Alliance NHS Confederation Welsh Health Specialised Services Committee Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (Iptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England MDO Olivical Trials Haif 		•
 and Infection Group British Society for Genetic Medicine British Society for Haematology British Society for Immunology National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Pathologists Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee NHS Alliance NHS Confederation Welsh Health Specialised Services Committee Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (Iptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England MHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee 	•	•
 British Society for Genetic Medicine British Society for Haematology British Society for Immunology National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health and Social Care NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (Iptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Cochrane Haematological Malignancies Group Cochrane UK Genomics England MDO Olivical Triate Unit 		
 British Society for Haematology British Society for Immunology National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health and Social Care Scottish Medicines Consortium Welsh Health Specialised Services Committee Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (Iptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England MDO Olivical Tricks Medicines 	·	
 National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Committee Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (Iptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England MDO Olivical Trials Mait	<u>-</u>	Scottish Medicines Consortium
 National PNH Service NHS Blood and Transplant Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health and Social Care Committee Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (Iptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England MDO Olivical Trials Mait 	British Society for Immunology	Welsh Health Specialised Services
 Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health and Social Care Comparator companies Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (Iptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Cochrane Haematological Malignancies Group Cochrane UK Genomics England MDO Olivical Trials Linit 	National PNH Service	
 Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health and Social Care Alexion Pharmaceuticals (eculizumab, ravulizumab) Novartis Pharmaceuticals (lptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England MPO Olivical Tricks Unit 	<u> </u>	
 Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health and Social Care ravulizumab) Novartis Pharmaceuticals (Iptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Cochrane Haematological Malignancies Group Cochrane UK Genomics England 	· · · · · · · · · · · · · · · · · · ·	
 Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health and Social Care Novartis Pharmaceuticals (Iptacopan) Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England MDO Olivical Trials Hait 	1	
 Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health and Social Care Swedish Orphan Biovitrum (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England MDC Oliviral Trials Hait 		,
 Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health and Social Care (pegcetacoplan) Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England 		
 UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health and Social Care Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England 		·
 UK Forum on Haemoglobin Disorders UK National Screening Committee Others Department of Health and Social Care Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England MDC Olivinal Trials Hait 	•	(pegcetacopian)
 UK National Screening Committee Others Department of Health and Social Care Cochrane Haematological Malignancies Group Cochrane UK Genomics England 		Relevant research groups
Others Others Department of Health and Social Care Group Cochrane UK Genomics England MDC Oliving Living Living		
Others Department of Health and Social Care Cochrane UK Genomics England MDC Official Trials Heit	UK National Screening Committee	
Department of Health and Social Care Genomics England MDC Olivinal Trials Heit	Others	·
MDO Olivis - I Trisla Hait		
	NHS England	1 100 00 1 1 7 1 11 0
 Welsh Government National Institute for Health Research 		National Institute for Health Research

Final stakeholder list for the evaluation of danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088] Issue date: September 2023

Consultees	Commentators (no right to submit or appeal)
	 Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Final stakeholder list for the evaluation of danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088] Issue date: September 2023

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.